← Back to Search

Messaging Strategies + Financial Incentive for Lung Cancer Screening Eligibility

N/A
Waitlist Available
Led By Katharine A Rendle, PhD,MSW,MPH
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet age eligibility (50-80 years old) for LCS based on 2021 USPSTF guidelines
Be older than 18 years old
Must not have
Have a documented history of lung cancer
Are listed as not wanting to be contacted or solicited for research
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests different messages to increase response rates to a survey that estimates eligibility for lung cancer screening. This helps improve future interventions to increase screening.

Who is the study for?
This trial is for people aged 50-80 who've had a primary care visit at Penn Medicine between 2020-2025 and are eligible for lung cancer screening. It's not for those with a history of lung cancer, who've completed lung cancer screening at Penn Medicine, or don't want to be contacted for research.
What is being tested?
The study is testing how different types of messages affect the response rates to a survey estimating eligibility for lung cancer screening. The goal is to find the most effective messaging strategy to encourage participation in future screenings.
What are the potential side effects?
Since this trial involves only receiving informational messages and completing surveys, there are no medical side effects associated with traditional clinical trials that test drugs or medical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a documented history of lung cancer.
Select...
I do not wish to be contacted for research purposes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Full Survey Completion
Secondary study objectives
Partial Survey Completion

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

12Treatment groups
Experimental Treatment
Group I: Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (CA) plus an incentive
Group II: Arm 8 (Introductory Message B + Tobacco Use Message B)Experimental Treatment2 Interventions
Participants will receive two framed messages (BB)
Group III: Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (BB) plus an incentive
Group IV: Arm 6 (Introductory Message B + Tobacco Use Message A)Experimental Treatment2 Interventions
Participants will receive two framed messages (BA)
Group V: Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (BA) plus an incentive
Group VI: Arm 4 (Introductory Message A + Tobacco Use Message B)Experimental Treatment2 Interventions
Participants will receive two framed messages (AB)
Group VII: Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (AB) plus an incentive
Group VIII: Arm 2 (Introductory Message A + Tobacco Use Message A)Experimental Treatment2 Interventions
Participants will receive two framed messages (AA)
Group IX: Arm 12 (Introductory Message C + Tobacco Use Message B)Experimental Treatment2 Interventions
Participants will receive two framed messages (CB)
Group X: Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (CB) plus an incentive
Group XI: Arm 10 (Introductory Message C + Tobacco Use Message A)Experimental Treatment2 Interventions
Participants will receive two framed message (CA)
Group XII: Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)Experimental Treatment3 Interventions
Participants will receive two framed messages (AA) plus an incentive
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Financial Incentive
2016
N/A
~133420

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,106,087 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,166,620 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
418 Previous Clinical Trials
458,122 Total Patients Enrolled
Katharine A Rendle, PhD,MSW,MPHPrincipal InvestigatorUniversity of Pennsylvania
2 Previous Clinical Trials
212 Total Patients Enrolled
~2483 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top